Changing paradigms in the follow-up of patients with differentiated thyroid cancer: An alternative to [18F]fluorodeoxyglucose positron emission tomographic scanning

Endocrine Practice

Volumn 9, Issue 4, 2003, Pages 324-326

  Mazzaferri, Ernest L ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; THYROTROPIN;

COMPUTER ASSISTED EMISSION TOMOGRAPHY; ECHOGRAPHY; HUMAN; NECK; NOTE; SCINTISCANNING; THYROID TUMOR;

FLUORODEOXYGLUCOSE F18; HUMANS; NECK; RADIOPHARMACEUTICALS; THYROID NEOPLASMS; THYROTROPIN; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 2142746971     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.9.4.324     Document Type: Editorial

References (25)

1. Mazzaferri EL, Kloos RT. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions. Thyroid. 2000;10:767-778.
2. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433-1441.
3. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab. 2003; 88:1107-1111.
4. Torlontano M, Crocetti U, D'Aloiso L, et al. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocrinol. 2003;148:19-24.
5. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab. 2002;87:3242-3247.
6. Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer. 2003;97:90-96.
7. Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid. 2003;13:3-126.
8. Demers LM, Spencer CA. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Clin Endocrinol (Oxf). 2003;58:138-140.
9. Gorges R, Eising EG, Fotescu D, et al. Diagnostic value of high-resolution B-mode and power-mode sonography in the follow-up of thyroid cancer. Eur J Ultrasound. 2003; 16:191-206.
10. Joensuu H, Klemi PJ, Eerola E. Diagnostic value of flow cytometric DNA determination combined with fine needle aspiration biopsy in thyroid tumors. Anal Quant Cytol Histol. 1987;9:328-334.
11. Alnafisi NS, Driedger AA, Coates G, Moote DJ, Raphael SJ. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med. 2000; 41:1010-1015.
12. Chung JK, So Y, Lee JS, et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med. 1999;40:986-992.
13. Hooft L, Hoekstra OS, Deville W, et al. Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:3779-3786.
14. Wang W, Macapinlac H, Larson SM, et al. [18F]-2-fluoro-2-deoxy-D- glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999;84: 2291-2302.
15. Van den Bruel A, Maes A, De Potter T, et al. Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. J Clin Endocrinol Metab. 2002;87:1517-1520.
16. Petrich T, Borner AR, Otto D, Hofmann M, Knapp WH. Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2002;29:641-647.
17. Wang W, Larson SM, Fazzari M, et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000;85:1107-1113.
18. Muros MA, Llamas-Elvira JM, Ramirez-Navarro A, et al. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. Am J Surg. 2000;179:457-461.
19. Grünwald F, Kalicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med. 1999;26:1547-1552.
20. Sarlis NJ, Gourgiotis L, Guthrie LC, et al. In-111 DTPA-octreotide scintigraphy for disease detection in metastatic thyroid cancer: comparison with F-18 FDG positron emission tomography and extensive conventional radiographic imaging. Clin Nucl Med. 2003;28:208-217.
21. Stokkel MP, de Klerk JH, Zelissen PM, Koppeschaar HP, van Rijk PP. Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: preliminary results. Eur J Nucl Med. 1999;26:1606-1609.
22. Tiepolt C, Beuthien-Baumann B, Hliscs R, et al. 18F-FDG for the staging of patients with differentiated thyroid cancer: comparison of a dual-head coincidence gamma camera with dedicated PET. Ann Nucl Med. 2000;14:339-345.
23. Moog F, Linke R, Manthey N, et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med. 2000;41:1989-1995.
24. Cohen MS, Arslan N, Dehdashti F, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery.2001;130:941-946.
25. Burguera B, Gharib H. Thyroid incidentalomas: prevalence, diagnosis, significance, and management. Endocrinol Metab Clin North Am. 2000;29:187-203.